Atlas Venture Fund X, L.p. - Net Worth and Insider Trading
Atlas Venture Fund X, L.p. Net Worth
The estimated net worth of Atlas Venture Fund X, L.p. is at least $409 Million dollars as of 2024-11-05. Atlas Venture Fund X, L.p. is the 10% Owner of Kymera Therapeutics Inc and owns about 5,504,905 shares of Kymera Therapeutics Inc (KYMR) stock worth over $260 Million. Atlas Venture Fund X, L.p. is the 10% Owner of Disc Medicine Inc and owns about 2,304,172 shares of Disc Medicine Inc (IRON) stock worth over $138 Million. Atlas Venture Fund X, L.p. is also the 10% Owner of Avrobio Inc and owns about 463,941 shares of Avrobio Inc (AVRO) stock worth over $8 Million. Besides these, Atlas Venture Fund X, L.p. also holds Magenta Therapeutics Inc (MGTA) . Details can be seen in Atlas Venture Fund X, L.p.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Atlas Venture Fund X, L.p. has not made any transactions after 2024-03-13 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Atlas Venture Fund X, L.p.
Atlas Venture Fund X, L.p. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Atlas Venture Fund X, L.p. owns 7 companies in total, including Replimune Group Inc (REPL) , Kymera Therapeutics Inc (KYMR) , and Generation Bio Co (GBIO) among others .
Click here to see the complete history of Atlas Venture Fund X, L.p.’s form 4 insider trades.
Insider Ownership Summary of Atlas Venture Fund X, L.p.
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| REPL | Replimune Group Inc | 2018-07-19 | 10 percent owner |
| KYMR | Kymera Therapeutics Inc | 2024-03-13 | 10 percent owner |
| GBIO | Generation Bio Co | 2020-06-11 | 10 percent owner |
 | | 2019-07-19 | 10 percent owner |
| | 2019-03-20 | 10 percent owner |
| | 2024-01-23 | 10 percent owner |
| | 2021-03-25 | 10 percent owner |
Atlas Venture Fund X, L.p. Latest Holdings Summary
Atlas Venture Fund X, L.p. currently owns a total of 4 stocks. Among these stocks, Atlas Venture Fund X, L.p. owns 5,504,905 shares of Kymera Therapeutics Inc (KYMR) as of March 13, 2024, with a value of $260 Million and a weighting of 63.55%. Atlas Venture Fund X, L.p. owns 2,304,172 shares of Disc Medicine Inc (IRON) as of January 23, 2024, with a value of $138 Million and a weighting of 33.84%. Atlas Venture Fund X, L.p. also owns 463,941 shares of Avrobio Inc (AVRO) as of July 19, 2019, with a value of $8 Million and a weighting of 1.91%. The other 1 stocks Magenta Therapeutics Inc (MGTA) have a combined weighting of 0.7% among all his current holdings.
Latest Holdings of Atlas Venture Fund X, L.p.
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| KYMR | Kymera Therapeutics Inc | 2024-03-13 | 5,504,905 | 47.17 | 259,666,369 |
| IRON | Disc Medicine Inc | 2024-01-23 | 2,304,172 | 60.01 | 138,261,841 |
| AVRO | Avrobio Inc | 2019-07-19 | 463,941 | 16.80 | 7,794,209 |
| MGTA | Magenta Therapeutics Inc | 2019-03-20 | 4,117,125 | 0.70 | 2,880,341 |
Holding Weightings of Atlas Venture Fund X, L.p.
Atlas Venture Fund X, L.p. Form 4 Trading Tracker
According to the SEC Form 4 filings, Atlas Venture Fund X, L.p. has made a total of 5 transactions in Kymera Therapeutics Inc (KYMR) over the past 5 years, including 0 buys and 5 sells. The most-recent trade in Kymera Therapeutics Inc is the sale of 353,357 shares on March 13, 2024, which brought Atlas Venture Fund X, L.p. around $15 Million.
According to the SEC Form 4 filings, Atlas Venture Fund X, L.p. has made a total of 5 transactions in Disc Medicine Inc (IRON) over the past 5 years, including 0 buys and 5 sells. The most-recent trade in Disc Medicine Inc is the sale of 150,000 shares on January 23, 2024, which brought Atlas Venture Fund X, L.p. around $10 Million.
According to the SEC Form 4 filings, Atlas Venture Fund X, L.p. has made a total of 0 transactions in Avrobio Inc (AVRO) over the past 5 years. The most-recent trade in Avrobio Inc is the acquisition of 67,568 shares on July 19, 2019, which cost Atlas Venture Fund X, L.p. around $15 Million.
More details on Atlas Venture Fund X, L.p.'s insider transactions can be found in the Insider Trading History of Atlas Venture Fund X, L.p. table.Insider Trading History of Atlas Venture Fund X, L.p.
- 1
Atlas Venture Fund X, L.p. Trading Performance
GuruFocus tracks the stock performance after each of Atlas Venture Fund X, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Atlas Venture Fund X, L.p. is -37.24%. GuruFocus also compares Atlas Venture Fund X, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Atlas Venture Fund X, L.p. within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Atlas Venture Fund X, L.p.'s insider trading performs compared to the benchmark.
Performance of Atlas Venture Fund X, L.p.
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -11.87 | | | | | |
| Relative Return to S&P 500(%) | -10.09 | | | | | |
Atlas Venture Fund X, L.p. Ownership Network
Ownership Network List of Atlas Venture Fund X, L.p.
Ownership Network Relation of Atlas Venture Fund X, L.p.
Atlas Venture Fund X, L.p. Owned Company Details
What does Replimune Group Inc do?
Who are the key executives at Replimune Group Inc?
Atlas Venture Fund X, L.p. is the 10 percent owner of Replimune Group Inc. Other key executives at Replimune Group Inc include Chief Financial Officer Emily Luisa Hill , Chief Medical Officer Konstantinos Xynos , and Chief Commercial Officer Christopher Sarchi .
Replimune Group Inc (REPL) Insider Trades Summary
Over the past 18 months, Atlas Venture Fund X, L.p. made no insider transaction in Replimune Group Inc (REPL). Other recent insider transactions involving Replimune Group Inc (REPL) include a net sale of 51,624 shares made by Pamela Esposito , a net sale of 30,332 shares made by Konstantinos Xynos , and a net sale of 41,467 shares made by Sushil Patel .
In summary, during the past 3 months, insiders sold 8,938 shares of Replimune Group Inc (REPL) in total and bought 0 shares, with a net sale of 8,938 shares. During the past 18 months, 282,095 shares of Replimune Group Inc (REPL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 282,095 shares.
Replimune Group Inc (REPL)'s detailed insider trading history can be found in Insider Trading Tracker table.
Replimune Group Inc Insider Transactions
Atlas Venture Fund X, L.p. Mailing Address
Above is the net worth, insider trading, and ownership report for Atlas Venture Fund X, L.p.. You might contact Atlas Venture Fund X, L.p. via mailing address: 400 Technology Square, 10th Floor, Cambridge Ma 02139.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
